INSIDE: - Medical Device Daily

MONDAY, OCTOBER 3, 2005 BIOWORLD ® FINANCIAL WATCH PAGE 6of 10Company Acquiring Date Expected Value Terms/DetailsTo Be Acquired* Company* Announced Completion (M)**(Country; Symbol) (Country; Symbol)Afmedica Inc.* Angiotech 9/13/05 4Q:05 ND Afmedica is developing perivascular tech-Pharmaceuticalsnology using the drug rapamycin to treatInc. (Canada; ANPI)various diseasesArtesian Cardiome 8/29/05 4Q:05 N/A Artesian shareholders can earn $32M inTherapeutics Pharma Corp. payments for development milestonesInc.* (Canada; CRME) related to each of two drug candidatesAsterand Pharmagene 9/19/05 4Q:05 £13 Asterand shareholders would get aboutInc.* plc (UK; LSE:PGN) (US$23.5) 54.2M shares in the deal, or 50% of themerged company; they also would be entitledto deferred payments in stock and cashBioCheck Inc.* OXIS 9/21/05 ND $6 The all-cash deal is contingent on OXIS’Internationalability to raise enough money to purchaseInc. (OTC BB:OXIS)at least 51% of BioCheck; the purchase pricecould increase for any remaining sharesBioFocus plc Galapagos NV 9/21/05 4Q:05 £20.2 Galapagos offered to pay 124 pence in(UK; AIM:BIO) (Belgium; (US$35.6) stock for each BioFocus share, a premiumEuronext:GLPG)of 121% to the Sept. 20 closing price; Bio-Focus would own about 30% of the combinedcompanyBioSource Invitrogen 7/26/05 4Q:05 $130 Invitrogen intends to strengthen its posi-International Corp. (IVGN) tion in proteomics through the all-cashInc. (BIOI)acquisitionCertain assets Maxim 4/21/05 4Q:05 ND As part of a restructuring, Calypte enteredof Calypte Biomedical a nonbinding letter of intent to sell itsBiomedical Corp. Inc.* urine EIA, serum Western Blot and urine(AMEX:HIV)Western Blot HIV in vitro diagnostics businessCardioGenics Medeorex Inc. 5/1 1/05 3Q:05 ND CardioGenics shareholders would getInc.* (OTC BB:MRXI) Medeorex stock representing 75% of themerged companyCellective MedImmune 9/14/05 4Q:05 ND MedImmune intends to pay cash andTherapeutics Inc. (MEDI) potential milestone payments to acquireInc.*Cellective, which is developing monoclonalantibodies that target B-cell antigensCengent Inncardio Inc. 4/1/05 2H:05 ND They signed a definitive agreement underTherapeutics (OTC BB:INDO) which Inncardio would acquire CengentInc.*Chiron Corp. Novartis AG 9/1/05 N/A $4.5B Novartis offered to pay $40 per share, or(CHIR) (Switzerland) $4.5 billion, for the 58% of Chiron it doesn’town; Chiron directors on Sept. 5 termedthe unsolicited offer “inadequate”To subscribe, please call BIOWORLD ® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.Copyright © 2005 Thomson BioWorld ® . Reproduction is strictly prohibited.